Remed Co

Remed Co Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Remed Co (302550.KQ) as of Nov 19, 2026 is 455.40 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 17.35 % — a change of 2,524.40% (higher).

Cash Conversion

455.40 %

YoY

2,524.40%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Remed Co is 2025 455.40 % . Cash Conversion Rate (OCF/Net Income) of Remed Co was 2024 17.35 % . It decreases by 2,524.40% higher compared to the previous year.

The Remed Co Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
4.31 KRW
Jan 1, 2019
73.86 KRW
Jan 1, 2020
-141.28 KRW
Jan 1, 2021
-463.83 KRW
Jan 1, 2022
130.29 KRW
Jan 1, 2023
438.92 KRW
Jan 1, 2024
17.35 KRW
Jan 1, 2025
455.40 KRW
The Remed Co Cash Conversion history
YEARCash ConversionYoY
455.40 %+2,524.40%
17.35 %-96.05%
438.92 %+236.89%
130.29 %-128.09%
-463.83 %+228.31%
-141.28 %-291.28%
73.86 %+1,614.47%
4.31 %-97.66%
184.20 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Remed Co Stock analysis

What does Remed Co do? REMED Co., Ltd. generates revenue through the manufacturing and sale of medical equipment, including transcranial magnetic stimulation (TMS) therapy machines, pain therapy machines, and biosignal and monitoring machines. Pain therapy machines encompass electromagnetic stimulation machines, extracorporeal shockwave therapy machines, and high intensity laser therapy machines. Biosignal and monitoring machines include patient monitors, fetal monitors, and electrocardiogram (ECG/EKG) machines. The company distributes these products domestically and internationally, targeting healthcare providers and medical facilities that require specialized therapeutic and monitoring solutions. The firm's product portfolio focuses on advanced medical devices for neurological and pain management, as well as patient monitoring. Transcranial magnetic stimulation (TMS) therapy machines are used for neurological treatments, while pain therapy machines address chronic pain conditions. Biosignal and monitoring machines support critical patient care, with electrocardiogram (ECG/EKG) machines being a key component. These products are sold to hospitals, clinics, and medical centers across domestic and overseas markets. REMED Co., Ltd. serves healthcare institutions that require specialized equipment for diagnosis, treatment, and monitoring. The domestic market includes hospitals and clinics in Daejeon, while overseas markets extend to international healthcare providers. The company’s revenue streams are derived from direct sales of its medical equipment, with no mention of additional services or licensing agreements in the business description. Remed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Remed Co stock

Cash Conversion Rate (OCF/Net Income) of Remed Co is 455.40 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Remed Co changed from 17.35 % to 455.40 %, representing a 2,524.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Remed Co since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Remed Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Remed Co

All Key Metrics — Remed Co